“…28,38,39,62,63 Whereas, controversial views are raised in terms of CRC treatment. 13,64,65 It yet reminds us that the influence of YY1 on the evolution process of CRC and different therapeutic regimens might be overlooked in the past. So far, there are sporadic clinical trials concerning YY1 as a prognostic predictor in breast cancer, follicular lymphoma, diffuse large B-cell lymphoma, endotoxemia, and pediatric sepsis 70,72,73,76 (Table 3).…”